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The ascomycin macrolactam pimecrolimus is a
novel in¯ammatory cytokine release inhibitor that so
far has not been administered systemically to
humans. In this phase I/II randomized double-blind,
placebo-controlled, multiple rising dose proof of
concept study psoriasis patients were treated with
oral pimecrolimus or placebo. Gene pro®ling identi-
®ed a common genomic pro®le with a downregula-
tion of genes associated with in¯ammation but no
changes in gene expression linked to drug-related
side-effects. A steady state of pimecrolimus was
reached after 5±10 d, Cmax, and area under the curve
(0±24) was 54.5 ng per ml and 589.9 ng h per ml,
respectively, at steady state at the highest dose.
There was clear clinical ef®cacy in patients receiving
20 mg pimecrolimus twice daily and 30 mg twice
daily with a reduction of Psoriasis Area and Severity
Index by 60% and 75%, respectively. Histopatho-
logically and immunopathologically there was a
reversion of the psoriatic phenotype towards normal.
There were no notable clinical, laboratory, kidney
function, or immunologic side-effects. We conclude
that pimecrolimus taken orally is highly effective in a
concentration-dependent manner in patients with
psoriasis and on a short-term basis it is well tolerated
and this is con®rmed by its pharmacogenomic pro-
®le. The latter also indicates that pimecrolimus
should be equally effective in other in¯ammatory
skin diseases. Key words: ascomycin/pharmacogenomics/
pharmacokinetics/pimecrolimus/psoriasis. J Invest Dermatol
119:876±887, 2002
A
ccumulating evidence suggests that psoriasis is an
autoreactive, in¯ammatory disorder based on a
chronically ongoing T cell response (Baker and Fry,
1992). This concept is supported by the clinical
observation that signs and symptoms of psoriasis can
be relieved by systemic immunosuppressive therapy employing
cyclosporine A (Ellis et al, 1986; Mihatsch and Wolff, 1992),
tacrolimus (Jegasothy et al, 1992), systemic monoclonal antibodies,
or fusion proteins directed to CD3 (Weinshenker et al, 1989) and
CD4 (Nicolas et al, 1991; Prinz et al, 1991; Morel et al, 1992;
Bachelez et al, 1998; Gottlieb et al, 2000b), CD11a (Gottlieb et al,
2000a), the high-af®nity interleukin (IL)-2 receptor, CD2, and
tumor necrosis factor (TNF)-a (Gottlieb et al, 1995a; Krueger et al,
2000; Mrowietz et al, 2000; Oh et al, 2000; Owen and Harrison,
2000; Chaudhari et al, 2001; Ellis and Krueger, 2001). The
ascomycin macrolactam derivative pimecrolimus is a novel selective
in¯ammatory cytokine release inhibitor (Grassberger et al, 1999;
Meingassner et al, 1997; Neckermann et al, 2000; Paul et al, 2000;
Wellington and Spencer, 2000), which has been shown to suppress
disease activity in atopic dermatitis (Van Leent et al, 1998; Harper
et al, 2001), contact dermatitis (Queille-Roussel et al, 2000), and
psoriasis (Mrowietz et al, 1998) when applied topically. Pimecro-
limus has never been administered systemically to humans and as, in
animal models, it exhibits high anti-in¯ammatory activity after
systemic application (Meingassner et al, 1997; Stuetz et al, 2001)1 and
combines this with a low potential for systemic immunosuppression
(Stuetz et al, 2001) we addressed the question whether pimecrolimus
could be considered a drug for the systemic treatment of patients
with psoriasis and possibly other in¯ammatory skin diseases. Here we
report on a randomized, double-blind, placebo-controlled proof of
concept phase I/II study that evaluates the pharmacogenomic and
pharmacokinetic pro®le and the ef®cacy, safety, and tolerability of
this drug as an oral treatment in psoriasis. To the best of our
knowledge, this is the ®rst study that includes pharmacogenomic
pro®ling of blood cells during therapy.
MATERIALS AND METHODS
Study design In this randomized, double-blind, placebo-controlled,
multiple rising dose study patients were screened between days ±21 and
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±2, baseline examinations were performed on days ±2 and ±1, and
treatment was given from days 1 to 28. Patients were hospitalized for
study weeks 1 and 2 and were further closely monitored as outpatients
on a daily basis during study weeks 3 and 4. From days 27 to 30,
patients were hospitalized again for pharmacokinetic pro®ling.
Outpatient follow-up was done on day 34 and at completion of study
between days 40 and 42.
Five consecutive cohorts of 10 patients each were treated with rising
doses of oral pimecrolimus (SDZ ASM 981, Elidelâ, provided by
Novartis Pharma AG, Basel, Switzerland) for 4 wk (eight patients in each
cohort) or with placebo (two patients in each cohort). Escalating doses
were 5 mg once daily, 10 mg once daily, 20 mg once daily, 20 mg
twice daily, and 30 mg twice daily. Start of the next higher dose level
was permitted only after demonstration of tolerability and safety at the
preceding lower dose. After discontinuation of treatment, patients were
followed-up for 2 wk with further follow-up at varying intervals up to
12 mo. All patients gave written informed consent and the protocol was
approved by the institutional review board. The study was conducted
according to the Declaration of Helsinki principles.
Patients We studied 50 patients older than 18 y of age with
moderate-to-severe chronic stable plaque type psoriasis for at least 3 y.
The severity of the psoriasis was assessed by using the Psoriasis Area and
Severity Index (PASI). A minimum PASI of 10 was required for
inclusion. Psoriasis should have been stable during the 2 wk prior to
entry into the screening phase and should require a systemic treatment
according to the investigator's judgement. Erythrodermic or pustular
psoriasis were excluded. All patients had no other important concurrent
diseases nor a history thereof and had not been treated with immuno-
suppressive agents, cytostatics, systemic corticosteroids, or radiation
therapy within 6 mo; psoralen + ultraviolet A photochemotherapy,
ultraviolet phototherapy, or other disease modifying drugs for 1 mo; and
topical therapy for 1 wk. Other exclusion criteria were of cytochrome-
inducing or inhibiting and nephrotoxic drugs prior to study; positive
serology for hepatitis B, C, and HIV serology as well as a history of
alcohol or drug abuse. The baseline characteristics and measures of
disease activity were similar in the treatment and placebo groups
(Table I). Forty-seven of 50 patients completed the study; three patients
withdrew or had to be excluded after 21, 24, and 28 d, respectively, of
treatment for reasons that were not related to therapy or adverse effects.
Gene pro®ling Blood samples were collected from patients in the
cohort receiving 30 mg pimecrolimus twice daily before and after 13 or
14 d of treatment and submitted to gene expression analysis. Extraction
of RNA from whole blood samples, the preparation of the target,
hybridization, and analysis of the arrays were performed as recommended
by the Expression Analysis Technical Manual (Affymetrix Inc., Santa
Clara, CA). Good quality total RNA was used to synthesize double-
Table I. Demographics
Pimecrolimus Placebo
Subjects entered 40 10
Completed 37a 10
Male/female 40/0 9/1
Mean age (y) [range] 39.5 [22±61] 42.2 [19±60]
Body weight (kg) [range] 82.9 [55±108] 81.2 [60±99]
PASI at baseline [range] 21.2 [10.4±44.4] 22.2 [10±44.4]
aOne patient treated with 10 mg once daily pimecrolimus withdrew his consent
after 21 d of treatment. One patient on 30 mg twice daily did not complete the
full PK pro®le on the 28th day and had to be excluded; one patient on 30 mg
twice daily withdrew on day 24 for external reasons.
Table II. Genes consistently modulated in pimecrolimus treated patientsa
Pathway/functions Gene Variation Description
Ascomycin target pathway Macrophilin-12 ¯¯ Cytosolic drug receptor
Calmodulin ¯¯ Regulation of intracellular calcium signaling
T cell activation pathway
Calcium modulating cyclophilin ligand
CAMLG
¯ T cell activation pathway downstream of the TCR
and upstream of calcineurin
NRGN Neuragranin ¯ Storage and release of calmodulin and calcium
Antigen presentation Ii Invariant chain, CD74 ¯¯ Associated with HLA class II molecule
HLA-E ¯¯ Class I like molecule recognized by natural killer
lymphocytes
HLA-F ¯¯ Class I like molecule: Induced by IFN-g
4-1BB ligand ­ Stimulates CD8+ T cells
Cellular metabolism Ribosomal proteins (> 50) ¯ to ¯¯¯
Nascent polypeptide associated complex ¯ Ribosomes binding to the reticulum membrane
Histones H3.3 and H2 ¯/¯¯ Chromatin structure
Cyclin D2 and D3 ¯¯¯/¯¯ Progression in G1 phase
Zinc ®nger protein ZNF141 ­ Anti-proliferative properties
Transcription factor, signaling EF-1 ¯¯¯ Elongation factor 1 d
HMG-17 ¯¯¯ DNA binding protein nonhistone
TF Iia ¯¯ Transcription factor
Tyrosine phosphatase ¯ Signal transduction
G gamma 11 ¯ Protein G signaling pathway
Chemotaxis and leukocyte migration L-selectin ¯¯ Leukocyte rolling. Migration
LFA1a/LFA1b ¯¯/¯¯ Migration at the in¯ammation site.
MIC-2 CD99 ¯¯¯ Regulates LFA-1/CAM-1 adhesion of lymphocytes
RANTES ¯¯¯ Chemoattractant for lymphocytes, monocytes, eosinophils,
basophils. T cell proliferation activation,
T helper 1 differentiation.
Release of in¯ammatory mediators
Platelet factor activation 4 ¯ Leukocyte recruitment, histamine release
Selectin P ligand SELPLG ¯¯ Interacts with P and L-selectins. CLA
In¯ammation Leukotriene A4 hydrolase ¯ Responsible for the synthesis of leukotriene B
FC-epsilon binding protein ¯¯¯ Galectin 3 release of in¯ammatory mediators
Thromboxane A2 receptor ¯¯ Smooth muscle contraction
Prostaglandin endoperoxide synthase 1 ¯¯¯ First step of leukotriene and thromboxane synthesis
Kallistatin ­ Inhibits kallikrein kininogenase
aMedian fold change for the seven treated patients: from ±2 fold to ±5 fold: ¯, from ±5.1 to ±10 fold: ¯¯, from ±10 to ±30: ¯¯¯, from ±30 to ±100: ¯¯¯¯, from +2 to +5: ­
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stranded cDNA using the Superscript Choice System (Life Technologies,
Grand Island, NY), the cDNA was then in vitro transcribed (MEGA
ScriptTM T7 kit, Ambion, Huntingdon, UK) to form biotin-labeled
cRNA. Labeled cRNA was hybridized to probe arrays for 16 h at 45°,
washed according to the EukGE-WSZ protocol (Affymetrix Inc.) and
stained with streptavidin±phycoerythrin conjugate. Arrays were scanned
twice with the Gene Arrayâ scanner (Affymetrix Inc.). The data were
analyzed using the NPGN (Novartis PharmacoGenomic Network,
Novartis Pharma AG, Basel, Switzerland) data base and GeneSpringâ
(Silicon Genetics, Redwood City, CA). The genes consistently modulated
in pimecrolimus-treated patients were sorted to build a pro®le.
Pharmacokinetics Pimecrolimus blood concentrations were
determined by radioimmunoassay (Queille-Roussel et al, 2000) in all
cohorts immediately before the morning dose on days 4, 6, 8, 10, and
21, during the washout period on days 30 and 34, and at study
completion (between days 40 and 42). Full pro®les (times 0, 0.5, 1, 2, 3,
4, 6, 8, 12, and 24 h postdose) were performed on days 1, 13, and 28.
Ef®cacy assessments The ef®cacy of SDZ ASM 981 was assessed by
means of the PASI score and by a global evaluation of the status of the
disease performed by the investigator.
The PASI was calculated by using the following procedures. The
head, trunk, upper limbs, and lower limbs were assessed separately for
erythema, in®ltration, and scaling. The average degree of severity of each
symptom in each of the four body parts was assigned a score of 0±4. The
area covered by lesions on each body part was estimated as a percentage
of the total area of that particular body part and a score from 0 to 6 was
then assigned. The total score for each body part was obtained by
multiplying the sum of the severity scores of the three basic lesions by
the area score, then multiplying the result by the constant weighted
value assigned to that body part. The sum of the scores of the individual
body parts gives the PASI, which, theoretically, can range from 0 to
72.The area evaluation for calculating PASI took into account the true
surface affected by psoriasis. Whenever possible, the PASI was assessed
by the same investigator for each subject.A global evaluation of the status
of the disease was rated by the investigator using the following qualitative
scale: totally clear (normal skin), almost clear, mild, mild±moderate,
moderate, moderate±severe, and severe. For documentation all patients
were photographed on days 0, 7, 14, 28 (or 29), and at completion of
the study. Whole body photographs and photographs of three selected
(indicator) lesions were taken on each occasion.
The PASI was determined at screening, at baseline, on days 7, 14, 28
(or 29), and at completion of study (days 40±42). A global dermatologic
evaluation was performed at baseline, on day 28 (or 29) at completion of
study, and at follow-up visits.
The referenced value for the PASI and the global evaluation of the
status of the disease was the value assessed at baseline.
Safety and tolerability assessments Physical examination, blood
pressure, heart rate, and electrocardiogram were performed and body
weight was determined at screening, baseline, on days 2, 4, 8, 14, 21,
28, and at study completion. Laboratory safety tests were done at
screening, at baseline, on days 2, 4, 8, 14, 21, and 28 and at study
completion. They included full blood biochemistry, hematology, and
urine analysis. Glomerular ®ltration rate (inulin clearance) and renal
plasma ¯ow (paraamino hippuric acid [PAH] clearance) were performed
at baseline, on days 13 and 28, and at completion of the study; and
glucose tolerance tests at baseline and on day 28 for the 20 mg twice
daily and 30 mg twice daily cohorts.
Immunologic investigations Skin tests (Immignostâ) for delayed
type hypersensitivity to a battery of recall antigens (tetanus toxoid,
diphtheria toxoid, streptococcal antigen, tuberculin, Candida albicans
antigen, Trichophyton mentagrophytes, and Proteus mirabilis antigens) were
performed in the 30 mg twice daily cohort at screening or within the
®rst week of treatment and within 2 mo after completion of the study.
Tests were performed on the volar aspect of the lower arm and repeat
tests were done on the other arm. Tests were read at 48 h and 72 h and
redness plus palpable induration were considered a positive reaction. For
Table III. Selected genes not modulated in pimecrolimus-treated patients
Pathway/function Gene
Lymphocyte markersa CD3 d, CD3 epsilon, CD8, granzyme B, granzyme A
Cytokinesb IL-1, IL-2Rg, IL-3R, IL-4R, IL-7, IL-8, IL-8R, IL-10, transforming growth factor b1±3
Apoptosis pathway and stress response CASP, FADB-like apoptosis regulator, caspase 2, 3, 4, 6, 7, 8, 10, Requiem, BCL-2
interacting killer, ubiquitin-like domain, member 1, stress-induced phosphoprotein 1,
microsomal glutathione S-transferase 2, esterase D, glutathione S-transferase p,
glutathione S-transferase M4, glutathione peroxidase 4




Granzyme B Granzyme A CD8 b CD3 e CD3 d
45 +3.4 +3.1 +3.4 +1.9 =
49 = = ±1.7 = =
41 +4.1 +2.6 ±1.2 +1.9 ±7
48 ±2.4 ±1.7 ±3.4 +1.7 ±1.9
46 +4.2 +2.3 +2.4 +2.3 +1.5
50 +4.5 +1.6 +1.3 +1.9 +1.1
42 = +1.6 = ±1.1 ±3.5
44 +10.8 ND ND ND ND




ND, nondetermined (data reported as non detected in the array data).
Table V. Other, selected early cytokine, and cytokine












IL-1 a 3 3 1 Unchanged
IL-1 receptor
antagonist
1 3 3 1 downregulated,
1 unchanged
IL-2 receptor g 1 0 6 Unchanged
IL-3 receptor a
(low af®nity)
3 1 3 1 upregulated,
1 unchanged
IL-4 receptor 2 1 4 Unchanged
IL-7 receptor 3 2 2 Unchanged
IL-8 3 2 2 Unchanged
IL-8 receptor a 2 4 1 1 downregulated,
1 unchanged
IL-8 receptor b 3 1 3 Unchanged
IL-9 receptor 3 1 3 Unchanged
IL-10 4 0 3 Unchanged
IL-10 receptor a 0 1 6 1 downregulated,
1 unchanged
IL-10 receptor b 0 4 3 1 downregulated,
1 unchanged
IL-14 1 4 2 2 downregulated
IL-17 1 4 2 Unchanged
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each patient and at each reading the number of positive reactions was
recorded and the diameters of test sites were measured and recorded in
millimeters.
Quantitative determination of lymphocyte subpopulations in the
peripheral blood were done by ¯ow cytometry and T lymphocyte
proliferation in response to ex-vivo stimulation with superantigens and
mitogen and cytokine production after ex-vivo stimulation were also
assessed. The blood samples were taken before treatment and after 4 wk
of treatment (day 29) with 20 mg once daily, 20 mg twice daily, or
30 mg twice daily pimecrolimus or placebo. For immuno¯uorescence
analysis a whole blood lysis method (Becton Dickinson, Erembodegem,
Belgium) was performed using directly labeled monoclonal antibodies to
CD3 (Becton Dickinson), CD4 (Dako AS, Glostrup, Denmark), CD8
(Dako), CD25 (Dako), CD56 (Becton Dickinson), CD19 (Dako), T cell
receptor (TCR) ab (Immunotech, Marseille, France), TCR-gd
(Immunotech), pan major histocompatibility complex class II (Dako),
and CD45 (Dako). The samples were analyzed on a FACSCalibur
instrument using the Paint A software (Becton Dickinson). Positive
lymphocyte gating strategy was based on scatter analysis and CD45
positivity, and calculated also in absolute numbers based on a blood
differential count obtained from the same blood sample. CD4, CD8, and
expression of the activation markers CD25 and major histocompatibility
complex class II were measured on CD3-positive lymphocytes.
For cell proliferation studies blood was drawn into a syringe pre®lled
with stabilizator free heparin (®nal concentration 50 U per ml) and
diluted 1 : 10 with X-VIVO 15 medium (BioWhittaker, Walkersville,
MD) supplemented with L-glutamine (Life Technologies). Two hundred
microliter aliquots of diluted whole blood were stimulated in U-
bottomed microtiter plates (Nunc, Roskilde, Denmark) in the presence
of a mixture of the superantigens SEA plus SEB (Sigma, St Louis, MO;
each at ®nal concentrations of 250 ng per ml and 62.5 ng per ml),
phytohemagglutinin (PHA) (Sigma; 4 mg per ml) or medium for 5 d.
During the ®nal 16 h of incubation the cultures were labeled with 1 mCi
Figure 1. (a) Median blood trough concentrations of pimecro-
limus throughout the study. Blood concentrations of pimecrolimus
increased in proportion to the dose and steady state as reached after days
5±10. (b) AUCt vs dose on day 28. AUCt increased in proportion to the
dose.
Figure 2. Clinical ef®cacy of pimecrolimus is shown for a patient
receiving 20 mg twice daily photographed on day 0 (a) and day
28 (b) and for a patient receiving 30 mg twice daily on day 0 (c)
and day 28 (d).
Figure 3. Clinical ef®cacy of pimecrolimus as assessed by percent
PASI change from baseline for the different dose levels. Ef®cacy is
clearly dose-related and re¯ects as PASI reduction of 60% and 75%,
respectively, on day 28 for doses of 20 mg twice daily (40 mg per day)
and 30 mg twice daily (60 mg per day).
Table VI. Summary of adverse eventsa
0 mg 5 mg 10 mg 20 mg 40 mg 60 mg
Feeling of warmth 1 1 3 7
Viral infection 1 1 1
Local infection 1
Pruritus 1 1
Headache 1 1 1
Vertigo/malaise 1 1 1
Paraesthesia 1
Light sensitivity 1
aThe only consistent adverse effect was a feeling of warmth. The viral infections
were episodes of common cold.
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3H-thymidine (NEN, Boston, MA) and the incorporated radioactivity
was measured using the Wallac Microbeta MeltiLex scintillation system.
For cytokine production a 1 ml aliquot of 1 : 10 diluted (X-VIVO 15
medium) whole blood was stimulated for 48 h with phytohemagglutinin
(4 mg per ml) plus phorbol myristate acetate (PMA; 10±7 M; Sigma) in
round-bottomed 15 ml tubes (Becton Dickinson), thereafter the super-
natant was analyzed for the presence of IL-2, IL4, IL-10, and interferon
(IFN)-g, and -a using standard sandwich enzyme-linked immunosorbent
assay methodology using commercially available monoclonal antibody
pairs (Pharmingen, San Diego, CA).
Biopsies Punch biopsies of lesional skin at baseline and on day 28 in
patients of the 20 mg once daily, 20 mg twice daily, and 30 mg twice
daily cohorts with pimecrolimus or placebo were evaluated for the
histomorphologic and immunohistochemical phenotype of psoriasis,
epidermal thickness, the state of differentiation, activation and
proliferation of keratinocytes, and the in¯ammatory in®ltrates employing
monoclonal antibodies to CD1a, CD3, CD4 (Dako AS, Glostrup,
Denmark), CD8, keratin-16, Ki-67, HLA-DR (Neomakers Inc., Union
City, CA) ®laggrin, and involucrin (Biomedical Technologies Inc.,
Stoughton, MA). For staining a tech made horizonTM (Dako) and for
evaluation a Zeiss Axioscope microscope using a color 3 chip camera
and a KS 400 3.0 image analysis system (Zeiss Viscon, Oberkochen,
Germany) were employed.
Statistical analyses Demographic variables were analyzed by
descriptive statistics and the numerical data of the safety assessments at
each evaluation time were calculated over all subjects. Pharmacokinetic
parameters [Cmax, tmax, area under the curve (AUC)0±24 h, trough
concentration] were derived by standard noncompartmental analysis
methods from the concentration±time pro®les measured on days 1, 13,
and 28. Attainment of steady state was evaluated by a linear regression of
log-transformed trough concentration vs day; drug accumulation by a
paired t test of log-transformed trough concentration and AUCt (area
under the concentration±time curve during a dosing interval [t] at steady
state); and dose-proportionality by an ANOVA on log-transformed dose-
normalized Cmax and AUCt.
Data collected on the PASI score were tabulated by dose and
appropriate summary statistics were performed on percentage of change
from baseline. For statistical evaluation of the in¯ammatory in®ltrate in
skin sections we used the SPSS 8.0 software for Windows. Data collected
for each cell population were analyzed using the paired Student's t test.
For the immunologic data in the peripheral blood, an ANOVA was
performed on the log-transformed ratio of data before and after
treatment. In addition, the change in the parameters before and after
treatment with pimecrolimus was compared with the relative change in
the placebo group. The software package SAS (Release 6.12 for
Windows-NT, SAS Institute Inc.) was used for data analysis.
Figure 4. (a) Median serum creatinine levels in the placebo and
various pimecrolimus [5 mg, 10 mg, 20 mg, 20 mg twice daily
(= 40 mg per day) and 30 mg twice daily (= 60 mg per day)] dose
groups. Serum creatinine never increased more than 30% compared
with baseline. There are no notable changes in the creatinine levels from
screening to end of study (EOS) scr: screening visit, BL: baseline. (b)
Percent change of serum creatinine from baseline at day 28 in the
different dose groups and placebo. The highest percent change from
baseline was seen in the 20 mg twice daily dose group, which exceeded
that of the 30 mg twice daily dose group that showed fewer changes
than the placebo group.
Figure 5. Glomerular ®ltration rates. Percent changes from baseline
BL at day 28 for the different dose groups and placebo. There are no
differences between pimecrolimus and placebo-treated patients. bid:
twice daily.
Figure 6. Renal plasma ¯ow. Percent changes from baseline (BL) at
day 28 for the different dose groups and placebo. There are no
signi®cant differences between the 5 mg, 20 mg twice daily, and 30 mg
twice daily pimecrolimus group and placebo-treated patients. The
increase of renal plasma ¯ow in the 10 mg pimecrolimus group is
unexplained. bid: twice daily.
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RESULTS
Gene expression analysis identi®es a common genomic
pro®le Blood samples subjected to gene expression analysis using
gene chips that allow the survey of 7129 genes permitted the
identi®cation of a common genomic pro®le of pimecrolimus
consisting of about 150 genes. A large majority of those genes was
downregulated and sorted into functional categories (Table II).
Pimecrolimus strongly downregulated the expression of genes
associated with the macrolactam target pathway (e.g., macrophilin-
12, calmodulin), cellular activation and proliferation (histone 2,
histone 3.3, cyclin D2), antigen presentation (Ii invariant chain,
CD74), to cellular metabolism, signal transduction, transcrip-
tion factors, and in¯ammatory mediators, such as leukotriene A4
hydrolase, prostaglandin endoperoxide synthase, and Galectin 3
(Table II). Kallistatin, an in¯ammation regulating protein, was
upregulated (Table II). Genes related to lymphocyte recruitment,
chemotaxis, and cellular migration (LFA-1, CLA, and L-selectin)
were also downregulated. No signi®cant changes in T lymphocyte
markers (CD3, CD8, and granzymes) could be detected at the
RNA expression level suggesting an absence of a systemic T cell
suppressive effect of the drug (Tables III and IV). In addition, no
change of expression was seen for transforming growth factor b1±3
(Table III) and for IL-1, IL-2, IL-8, and IL-10 ( Tables III and
V). None of the genes that changed expression were clearly related
to side-effects or toxicity, and genes associated with apoptosis,
stress, and enzymatic induction were not changing expression
(Table III). Of course, data presented here pertain to blood only as
internal organs were not biopsied. For reasons of space the details of
these investigations will be published separately in detail.
Pharmacokinetics of pimecrolimus reveal rapid absorption,
attainment of steady state after 5±10 d, and linear dose
dependency at steady state Pimecrolimus was rapidly
absorbed; median tmax was between 0.8 and 2.0 h across all the
dose groups and collection days. Both Cmax (once daily dose
groups) and AUC(0±24) (both once daily and twice daily groups)
increased broadly in proportion to the dose (Fig 1). Some
statistically signi®cant deviations from ideal dose proportionality
were observed, but these were of a minor nature and may have
resulted from the high variability observed in the small number of
patients per group. Steady state was reached after days 5±10 and at
daily administration of 30 mg twice daily, Cmax and AUC0±24
reached 54.5 ng per ml and 589.9 ng h per ml at steady state,
respectively (Fig 1). In the 30 mg twice daily cohort, median
trough concentrations increased from 6 ng per ml on day 1 to
about 15 ng per ml at steady state (Fig 1).
Figure 7. Skin biopsy of a patient receiving 30 mg pimecrolimus
twice daily at baseline (a) and day 28 (b). Section stained for the
epidermal proliferation-associated keratin-16 (red). Note signi®cant
reduction of epidermal thickness, in¯ammatory in®ltrate, parakeratosis,
and loss of keratin 16 staining at the end of the treatment period. This is
a reversal of the psoriatic phenotype to almost normal. (c) Shows a
section stained for proliferating Ki-67+ keratinocytes. Note signi®cant
reduction of Ki-67+ nuclei at end of treatment (d) that accompanies the
reduction of acanthosis to that of a normal looking epidermis.
Figure 8. Ki-67 proliferating keratinocytes at baseline (day 0) and
day 28 in a 30 mg twice daily (60 mg) pimecrolimus and
placebo-treated patient. Note the signi®cant reduction of Ki-67
positive cells (p = 0.02) under pimecrolimus as compared with placebo.
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Pimecrolimus is highly effective in suppressing
psoriasis Whereas there was no change in disease activity and
PASI scores in the patients on placebo and the cohorts receiving
once daily pimecrolimus at 5 mg, 10 mg, and 20 mg, there was
clear ef®cacy in the cohorts receiving 20 mg pimecrolimus twice
daily and 30 mg twice daily. This involved a reduction of scaling,
erythema, and in®ltration of lesions and led to a reduction of PASI
score and even to an almost complete or complete clearing of
lesions on day 28 (one patient in the 20 mg twice daily and two
patients in the 30 mg twice daily cohorts) (Fig 2). This response
was clearly concentration related as shown in Fig 3. The mean
reduction of PASI (change from baseline at day 28) was 60% for the
20 mg twice daily and 75% for the 30 mg twice daily cohorts
(Fig 3).
Pimecrolimus is well tolerated and lacks notable clinical and
laboratory side-effects There were no clinically notable and
signi®cant changes in physical examination, blood pressure, heart
rate, and electrocardiogram at all concentrations of pimecrolimus
throughout the study (Table VI). The only consistent side-effect
recorded was a transient feeling of warmth occurring about 40 min
after ingestion of the drug in 10 patients in the 20 mg twice daily
and 30 mg twice daily cohorts, localized to the upper chest and
lasting for approximately 90 min. This sensation did not occur
every time after drug intake and in 75% of all cases it did not occur
more often than three times during the study. Fifty-eight percent of
these events occurred on the ®rst day of drug intake, 75% of them
occurred during the ®rst 10 d of the study, and 25% between days
21 and 28 (data not shown). The sensation of warmth was not a
matter of concern for the patients.
Hematology and blood chemistry revealed no clinically signi®-
cant changes throughout the study (data not shown).
Special attention was paid to blood urea nitrogen and serum
creatinine. There was no notable change from baseline in blood
urea nitrogen, and in serum creatinine at any concentration
(Fig 4). Blood urea nitrogen never increased more than 60%
compared with baseline. Serum creatinine never exceeded
150 mmol per liter in any treatment or in the placebo group.
Serum creatinine never increased more than 30% compared with
baseline (Fig 4) except for two patients treated with pimecrolimus
Figure 9. Reduction of lymphocytic in®ltrate and unchanged numbers of CD1a+ cells (Langerhans cells) during pimecrolimus
treatment. (a) CD3+ cells in psoriatic epidermis and dermis at days 0 and 28 at dose levels of 20 mg, 40 mg (= 20 mg twice daily), and 60 mg
(= 30 mg twice daily). The reduction of CD3+ cells at dose levels of 20 mg in the epidermis (p = 0.009) and dermis (p = 0.04) and of 60 mg
(= 30 mg twice daily) in the epidermis (p = 0.05) and dermis (p = 0.006) are signi®cant. (b) CD4+ cells are signi®cantly reduced at day 28 both in the
epidermis (p = 0.02) and dermis (p = 0.01) at the 60 mg (30 mg twice daily) dose level of pimecrolimus. (c) Pimecrolimus reduces CD8 cells in
epidermis and dermis, at all dose levels. The reduction of CD8+ cells in the dermis at 60 mg (30 mg twice daily) is signi®cant (p = 0.077). (d)
Pimecrolimus does not signi®cantly affect CD1a+ cells in the epidermis and dermis at any of the dose levels of pimecrolimus (e.g., 60 mg per day
epidermis p = 0.958; dermis p = 0.887).
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Figure 10. Skin tests for recall antigens in the 30 mg pimecrolimus twice daily patient cohort. Numbers in the right upper corner indicate
patient number, patients marked with P are patients on placebo; blue bars indicate pretreatment readings, red bars post-treatment readings, A±H refer
to antigens tested: (A) tetanus toxoid; (B) diphtheria toxoid; (C) streptococcal antigen; (D) tuberculin; (E) control; (F) Candida albicans; (G) Trichophyton
mentagrophytes; (H) Proteus mirabilis antigens. The ®gures on the ordinate are diameters in millimeters of positive reactions. There are no consistent
changes from pretreatment to post-treatment skin reactions to the recall antigens tested.
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20 mg twice daily who had an isolated increase of 30% at day 8 and
44% at day 14, respectively. But on days 21 and 28, and for the end
of study visit serum creatinine was within the normal range in these
patients. Glomerular ®ltration rate determined by inulin clearance
and renal plasma ¯ow determined by PAH clearance were
performed at baseline, day 13, day 28, and completion of study.
Glomerular ®ltration rate (Fig 5) and renal plasma ¯ow (Fig 6)
¯uctuated more than creatinine but showed no trend for a decrease
in the pimecrolimus-treated patients in comparison with the
placebo-treated patients, nor with increasing doses of pimecroli-
mus.
Glucose tolerance tests were normal.
Histopathologically and immunopathologically pimecro-
limus reverses the psoriatic phenotype to normal Histo-
pathologic and immunopathologic examination of biopsies taken
from the patients in the 20 mg once daily, 20 mg twice daily, and
30 mg twice daily cohorts were in accordance with the clinical
®ndings and were most pronounced in the 30 mg twice daily
cohort. Pimecrolimus induced an almost complete reversion of
psoriatic epidermal hyperplasia and a marked reduction of the
in¯ammatory in®ltrate at 28 d of treatment (Fig 7a,b). There was a
signi®cant reduction of epidermal thickness, the expression of the
proliferation-associated keratin 16 (Fig 7a,b) and the proliferating,
i.e., Ki-67+ keratinocytes (Figs 7c,d and 8). Staining patterns of
involucrin and ®laggrin reverted from that typical for psoriasis to
near that of normal epidermis (data not shown). Keratinocyte
activation (HLA-DR and intercellular adhesion molecule-1
staining) was signi®cantly reduced or abolished (data not shown).
There was a signi®cant reduction of CD3+, CD4+, and CD8+
dermal lymphocytes (Fig 9a±c), and a signi®cant reduction of
CD3+ and CD4+ epidermal lymphocytes; CD8+ epidermal
lymphocytes were also reduced but this did not reach the level of
signi®cance (Fig 9a±c); there were no signi®cant changes in the
CD1a+ cell population both in the epidermis and dermis (Fig 9d)
and there was an involution of the proliferating papillary blood
vessels and their activation markers (data not shown).
Similar albeit lesser changes were also seen in the 20 mg once
daily cohort (see Fig 9a,b) where no noticeable effect of
pimecrolimus on psoriasis was evident clinically. Placebo-treated
patients retained the full complement of the histopathologic and
immunopathologic phenotype of psoriasis (data not shown).
Pimecrolimus leaves immunologic parameters unaffec-
ted Intradermal testing for delayed hypersensitivity reactions to
recall antigens showed no signi®cant changes from pretreatment to
post-treatment testing for the pimecrolimus and placebo-treated
patients (Fig 10). Flow cytometry analysis of blood lymphocyte
subpopulations revealed no signi®cant differences between
treatment groups, and placebo patients (Tables VII and VIII).
With the exception of a signi®cant increase of the proliferation
response to superantigen at a 250 ng per ml concentration in the
placebo patients and in the 20 mg once daily cohort no consistent
and signi®cant changes or patterns were seen in the proliferation of
Table VII Fluorescence-activated cell sorter analysis: comparison of lymphocyte subpopulations before and after
treatment, ANOVA results
Description










Leuko (g per l) 1.05 1.10 0.97 0.719 0.282 0.715
% Lympho 1.20 1.22 1.02 0.199 0.058 0.884
Lympho (g per l) 1.26 1.34a 0.98 0.130 0.010 0.882
CD3 (% of leuco) 1.23 1.17 1.07 0.195 0.168 0.586
CD4 (% of leuco) 1.26 1.20 1.10 0.142 0.099 0.426
CD8 (% of leuco) 1.15 1.21 1.05 0.409 0.132 0.713
CD56 (% of leuco) 1.02 1.35a 0.81 0.911 0.036 0.151
CD19 (% of leuco) 1.39 1.29a 1.24 0.072 0.049 0.120
TCR-ab (% of leuco) 1.19 1.20 0.391 0.094
TCR-gd (% of leuco) 0.95 1.17 0.808 0.181
CD3 + 25 (% of leuco) 1.32 1.05 0.80 0.456 0.838 0.411
CD3 + HLA DR (% of leuco) 1.40 1.29 0.80 0.138 0.115 0.195
CD3 (% of lympho) 1.03 0.96 1.05 0.567 0.218 0.154
CD4 (% of lympho) 1.05 0.99 1.08a 0.273 0.648 0.025
CD8 (% of lympho) 0.96 0.99 1.03 0.493 0.851 0.469
CD56 (% of lympho) 0.58 1.11 0.80 0.322 0.388 0.081
CD19 (% of lympho) 1.16 1.06 1.22a 0.106 0.342 0.008
TCR-ab (% of lympho) 0.95 0.98 0.115 0.298
TCR-gd (% of lympho) 0.75 0.96 0.338 0.783
CD3 (g per l) 1.29 1.29a 1.03 0.131 0.039 0.786
CD4 (g per l) 1.32 1.32a 1.06 0.107 0.025 0.614
CD8 (g per l) 1.21 1.33a 1.02 0.274 0.025 0.899
CD56 (g per l) 1.08 1.49a 0.79 0.694 0.011 0.131
CD19 (g per l) 1.46 1.41a 1.20 0.062 0.020 0.219
TCR-ab (g per l) 1.36 1.32a 0.229 0.046
TCR-gd (g per l) 1.08 1.38a 0.764 0.032
CD3+25 (g per l) 1.34 1.28 0.84 0.469 0.386 0.577
CD3 + HLA DR (g per l) 1.41 1.42 0.79 0.162 0.050 0.193
CD25 (% of CD3) 1.07 0.90 0.75 0.857 0.678 0.282
HLA DR (% of CD3) 1.13 1.10 0.75 0.547 0.520 0.084
aRatio statistically signi®cantly different from 1.
In this table the parameter values before treatment and after 4 wk of treatment were compared for the placebo group and each of the treatment groups (20 mg once daily
and 30 mg twice daily pimecrolimus). Example: For the lymphocytes (Lympho g per l), the ratio of the number of lymphocytes after treatment to the number of lympho-
cytes before treatment was estimated as 1.26 in the placebo group, i.e., the number of lymphocytes increased by 26% in the placebo group; however, this increase was not
statistically signi®cant (p-value = 0.130, > 0.05). In the 20 mg once daily group, the number of lymphocytes increased by 34%, which was statistically (p-value = 0.010). In
the 30 mg twice daily group, the number of lymphocytes slightly decreased by 2% (p-value = 0.882, not statistically signi®cant). leuco, leucocytes; lympho, lymphocytes.
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lymphocytes (examples shown in Table IX); also, no consistent
patterns were seen in cytokine release before and after 4 wk of
treatment (examples shown in Table X).
Follow-up shows recurrence of psoriasis after 8 wk but no
rebound The 20 patients of the 20 mg twice daily and 30 mg
twice daily cohorts, four of whom had received placebo, were
followed at varying intervals up to 12 mo. Twelve of the
responders had a recurrence after 8 wk after termination of
treatment (median 6 wk, range 4±20 wk). Recurrences were as
follows: seven of 12 had a full recurrence (100% of original PASI),
three of 12 a recurrence up to 80%, and two of 12, 30% of original
PASI. Rebound effects (i.e., worsening of psoriasis over baseline)
were not noted.
DISCUSSION
In this study we show that the ascomycin macrolactam pimecro-
limus: (i) has a gene pro®le of broad anti-in¯ammatory activity
without evidence of toxicity as evaluated in blood cells; (ii) exhibits
excellent clinical tolerability after 4 wk of oral treatment up to the
highest dose tested (30 mg twice daily); (iii) after multiple oral
treatments blood concentrations reach steady state after 5±10 d and
drug exposure at a steady state is linearly concentration dependent;
and (iv) given in doses of 20 mg twice daily and 30 mg twice daily
pimecrolimus is highly effective in a concentration-dependent
manner in patients with moderate to severe plaque psoriasis.
Pimecrolimus is a selective inhibitor of in¯ammatory cytokines
in vitro. By binding to macrophilin-12 it inhibits the Ca-dependent
phosphatase calcineurin1 and by blocking the transcription of early
cytokines and thus downregulating, at nanomolar concentrations,
both T helper 1 and 2 type cytokine synthesis (Grassberger et al,
1999) it inhibits T cell activation in vitro. Not surprisingly,
pimecrolimus exhibits high anti-in¯ammatory activity in animal
models of skin in¯ammation both topically and systemically
(Meingassner et al, 1997; Neckermann et al, 2000). Its potency in
skin in¯ammation models is comparable with that of dexametha-
sone after topical application and, when given systemically, it
exceeds that of cyclosporine A by factors ranging from 2 to 4 and is
equally effective or superior to tacrolimus depending on the model
chosen (Meingassner et al, 1997; Stuetz et al, 2001). By contrast, in
animal models of systemic immunosuppression it has only low
activity when compared with cyclosporine A and tacrolimus
(Stuetz et al, 2001). For instance, in the rat kidney transplantation
model an oral dose three times higher than that of cyclosporine A
and 15 times higher than that of tacrolimus is required to prevent
kidney rejection and in a model of localized graft versus host
reaction, pimecrolimus is less potent than cyclosporine and
tacrolimus in suppressing graft versus host reactions by a factor of
8 and 66, respectively (Stuetz et al, 2001). In contrast to
cyclosporine and tacrolimus the oral treatment of mice with
pimecrolimus neither impairs the primary immune response nor
decreases the lymph node weight and cellularity in allergic contact
dermatitis (Meingassner et al, 2000). These data indicate that
pimecrolimus has unique pharmacologic properties by combining
high skin-selective anti-in¯ammatory activity with a low potential
for systemic immune responses, suggesting its suitability for
treatment of T cell-mediated autoreactive in¯ammatory reactions
of the skin in humans.
In this study it has been shown that pimecrolimus is highly
effective in psoriasis in a concentration-dependent manner. The
impressive clinical ef®cacy of pimecrolimus compares favorably
with that of established systemic treatments for psoriasis, such as
psoralen + ultraviolet A photochemotherapy and oral retinoid±
psoralen + ultraviolet A combinations (HoÈnigsmann et al, 1994),
methotrexate (Linden and Weinstein, 1999), and cyclosporine A
(Lebwohl et al, 1998). Clinical remission of psoriasis was accom-
panied by corresponding histopathologic and immunomorphologic
reversion of the psoriatic to a normal or almost normal phenotype.
Curiously, a signi®cant reduction of CD3+ and CD4+ T cells was
observed in the 20 mg pimecrolimus once daily cohort without
clinical improvement. This may be taken to indicate that treatment
for a prolonged time may result in clinical effectiveness even at
lower doses of the drug.
To the best of our knowledge the gene expression analysis
reported here is one of the ®rst of its kind and the results shown are
consistent with the observed clinical ef®cacy and the tolerability of
pimecrolimus. Whereas pimecrolimus was shown to downregulate
expression of genes strongly for the target pathway, in¯ammation,
activation, proliferation, chemotaxis, and migration of leukocytes,
and it did not reveal changes in gene expression that might be
linked to treatment-related immunosuppression and toxicity. The
predictive value of such pharmacogenomic investigations has to be
con®rmed but the data presented here harmonize with the
observed ef®cacy and tolerability of the drug.
No impairment of organ function as assessed by clinical and
laboratory examinations and no systemic immunosuppression was
noted in this study and no viral infections were seen throughout the
time patients were followed. This appears to verify the observation
in animal models where pimecrolimus was shown to have high
skin-selective anti-in¯ammatory activity and a very low potential
for effecting systemic immune responses (Stuetz et al, 2001). There
were three episodes of minor common cold. The feeling of warmth
noted as the only consistent adverse effect in our patients is as yet
unexplained. Although it appears to be concentration dependent it
Table VIII. Fluorescence-activated cell sorter analysis:


















Leuko (g per l) 1.05 0.92 0.735 0.613
% Lympho 1.01 0.84 0.935 0.342
Lympho (g per l) 1.07 0.78 0.714 0.191
CD3 (% of leuco) 0.95 0.87 0.790 0.468
CD4 (% of leuco) 0.96 0.87 0.806 0.470
CD8 (% of leuco) 1.05 0.91 0.825 0.659
CD56 (% of leuco) 1.32 0.79 0.238 0.333
CD19 (% of leuco) 0.93 0.89 0.733 0.590
TCR ab (% of leuco) 1.01 0.971
TCR gd (% of leuco) 1.23 0.405
CD3 + 25 (% of leuco) 0.80 0.60 0.622 0.280
CD3 + HLA DR
(% of leuco)
0.92 0.57 0.760 0.056
CD3 (% of lympho) 0.94 1.02 0.241 0.668
CD4 (% of lympho) 0.94 1.03 0.250 0.563
CD8 (% of lympho) 1.03 1.08 0.650 0.329
CD56 (% of lympho) 1.30 0.94 0.197 0.760
CD19 (% of lympho) 0.92 1.05 0.418 0.641
TCR-ab (% of lympho) 1.04 0.310
TCR-gd (% of lympho) 1.27 0.456
CD3 (g per l) 1.00 0.80 0.998 0.286
CD4 (g per l) 1.01 0.81 0.976 0.308
CD 8 (g per l) 1.11 0.84 0.625 0.422
CD56 (g per l) 1.38 0.73 0.203 0.219
CD19 (g per l) 0.96 0.82 0.878 0.417
TCR-ab (g per l) 0.97 0.914
TCR-gd (g per l) 1.28 0.402
CD3 + 25 (g per l) 0.96 0.63 0.929 0.364
CD3 + HLA DR (g per l) 1.01 0.56 0980 0.064
CD25 (% of CD3) 0.84 0.70 0.699 0.426
HLA DR (% of CD3) 0.97 0.66 0.904 0.129
aRatio statistically signi®cantly different from 1.
In this table the changes in parameter values before and after treatment with
pimecrolimus were compared with the corresponding changes in the placebo
group. Leuco, leucocytes; lympho, lymphocytes.
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does not occur after every drug dose and is not associated with any
other systemic or laboratory abnormality. Assessments of circulating
or locally released mediators, including neuropeptides, were not
performed during the heat episodes.
The ef®cacy in psoriasis and short-term safety of pimecrolimus
are most encouraging. Issues to be dealt with in the future include:
safety pro®le of pimecrolimus when it is administered in these and
lower doses over a longer period of time; determination of the
number of people who achieved greater than 90% improvement
and determining if response is consistent with recurrent courses of
therapy. Multicenter trials are in progress to answer these and other
questions. Independent of this our studies seem to indicate that the
anti-in¯ammatory qualities of pimecrolimus are indeed unique and
support the notion that pimecrolimus may be effective for other T
cell-mediated skin diseases.
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Table X. (a) Cytokines: comparison of parameters before and after treatment, ANOVA results
Description










IL-2 (pg per ml) medium 1.51 1.31 0.405 0.283
IL-2 (pg per ml) PHA + PMA 0.85 0.85 0.744 0.516
IL-4 (pg per ml) medium 1.86 0.74 1.63 0.184 0.356 0.165
IL-4 (pg per ml) PHA + PMA 0.92 1.45a 1.71a 0.706 0.029 0.005
IFN-g (pg per ml) medium 3.71a 0.42 0.23a 0.039 0.051 0.005
IFN-g (pg per ml) PHA + PMA 0.93 1.47 1.11 0.800 0.078 0.637
IL-10 (pg per ml) medium 3.48a 0.99 0.027 0.976
IL-10 (pg per ml) PHA + PMA 1.20 1.30a 0.241 0.006
TNF-a medium 1.37 1.03 0.693 0.948
TNF-a PHA + PMA 1.20 0.93 0.799 0.839
aRatio statistically signi®cantly different from 1.
The parameter values before treatment and after 4 wk of treatment were compared for the placebo group and each of the treatment groups. Statistically signi®cant
increases were identi®ed for the placebo group (IFN-gpg per ml medium, IL-10 pg per ml medium), the 20 mg once daily group (IL-4 pg per ml PHA + PMA, IL10 pg
per ml PHA + PMA) and the 30 mg twice daily group (IL-4 pg per ml PHA + PMA, IFN-gpg per ml medium).
(b) Cytokines: comparison of parameter changes treatment vs placebo, ANOVA results
Description









IL-2 (pg per ml) medium 0.87 0.793
IL-2 (pg per ml) PHA + PMA 1.00 0.999
IL-4 (pg per ml) medium 0.40 0.88 0.112 0.821
IL-4 (pg per ml) PHA + PMA 1.58 1.86a 0.109 0.039
IFN-g (pg per ml) medium 0.11a 0.06a 0.008 0.002
IFN-g (pg per ml) PHA + PMA 1.58 1.20 0.212 0.627
IL-10 (pg per ml) medium 0.29a 0.042
IL-10 (pg per ml) PHA + PMA 1.09 0.609
TNF-a medium 0.75 0.745
TNF-a PHA + PMA 0.77 0.750
aRatio statistically signi®cantly different from 1.
The changes in parameter values before and after treatment with pimecrolimus were compared with the corresponding changes in the placebo group. Statistically signi®-
cant differences were observed for IL-4 (pg per ml) PHA + PMA (placebo vs 30 mg twice daily), IFN-g(pg per ml) (placebo vs 20 mg once daily) and IL-10 (pg per ml)
medium.
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